Tag Archives: AstraZeneca

CRISPR Tx, AZ, and MiNK Tx Report Data in Solid Tumors; AACR 2024 Analysis 1

AACR 2024 Analysis 1: CRISPR Tx, AZ and MiNK Tx presented clinical and preclinical updates from their programs in solid tumors. Below, Celltelligence provides insights and key context for selected presentations. The following topics are covered: 

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Gracell’s GC012F Receives IND Clearance in Early Line MM

On Monday, January 29, Gracell announced (press release) that the FDA cleared the IND application to start a Ph1 trial to evaluate GC012F (BCMA x CD19 FasTCAR-T) in early line MM. Below, Celltelligence provides insights on Gracell’s major regulatory milestone, while discussing the importance of this trial for AstraZeneca’s cell therapy franchise.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

JPM 2024 Analysis Day 2: Legend, AstraZeneca, and BioNTech

On the second day of JPM 2024, Celltelligence covered presentations by Legend (presentation / webcast), AstraZeneca (presentation / webcast), and BioNTech (presentation / webcast). Below, Celltelligence provides insights and context for each presentation. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

We’re Back! Holiday Recap Ahead of JPM 2024 (Blast 1/2): Thoughts on AstraZeneca’s Acquisition of Gracell

Happy New Year! It’s great to be back in 2024 serving our growing audience!

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Carisma Tx Shows Initial Results from its Collaboration with Moderna; AstraZeneca Presents AZD6422’s Preclinical Development in Gastrointestinal Cancers and a Synergistic Combination of AZD074 with Enzalutamide in Prostate Cancer; SITC 2023 Analysis 1

SITC 2023 Analysis 1: Carisma Tx and AstraZeneca presented preclinical data from their novel cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

AstraZeneca and Cellectis Enter into Collaboration to Develop up to 10 Novel Cell and Gene Therapy Candidates Leveraging Cellectis’s Gene Editing Technologies and Manufacturing Capabilities

On Wednesday, November 1, AstraZeneca (press release) and Cellectis (press release) announced they entered into a strategic collaboration and investment agreement for the development of up to 10 novel cell and gene therapy candidate products in areas of high unmet need, including oncology, immunology, and rare diseases. Below, Celltelligence provides insights on the partnership, analyzes Cellectis’s TALEN-based gene-editing platform, and discusses how both companies could benefit from the collaboration.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Gilead to Initiate Trial to Evaluate New KITE-197 Asset in LBCL; AstraZeneca to Start Clinical Development of AZD5851 in HCC patients

On October 12, a new Gilead (Kite)-sponsored Ph1 trial investigating KITE-197, a novel asset with an undisclosed target, in r/r LBCL patients was posted on CT.gov. Additionally, on October 16, a new AZ-sponsored Ph1/2 ATHENA trial evaluating AZD5851 (TGFβRIIDN armored GPC3 CAR-T) in ≥2L GPC3 positive advanced / recurrent HCC was detected. Below, Celltelligence discusses the potential targets of KITE-197 while evaluating the relevance of the new AZ-sponsored clinical trial and the competitive advantage of AZD5851 over other GPC3 CAR-Ts.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

You May Have Missed: CARsgen Partners with Moderna; AZ to Collaborate in the Development of a New CAR-T in Solid Tumors; Gilead to Evaluate Novel Dual CAR-T; Poseida and Roche Publish P-CD19CD20-ALLO1’s New Trial; Germany’s G-BA Completes Carvykti’s Reimbursement – August 2023 Recap (Blast 1/2)

In August 2023, the Celltelligence team detected several relevant news items that were not discussed in individual blasts but are also worth highlighting. Celltelligence will publish a two-part series discussing the news and providing insights about their importance in the cell therapy space. In this first summary, the following topics are covered:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

AstraZeneca and Innovative Cellular Therapeutics Report Clinical Data in Solid Tumors; AACR 2023 Analysis 3

AACR 2023 Analysis 3: AstraZeneca (AZ), and Innovative Cellular Therapeutics (ICT) presented clinical updates on their CAR-T assets for solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on AstraZeneca’s Cell Therapy Pipeline

On Monday, January 16, AstraZeneca (AZ) announced (press release) the completion of Neogene Therapeutics’ acquisition for developing TCR-T therapies in solid tumors. Moreover, during JPM 2023, AZ introduced (presentation) AZD5851 (GPC3 armored CAR-T), its first official cell therapy program. Below, Celltelligence provides insights on AstraZeneca’s increasing interest in cell therapies, while discussing the potential of its innovative cell therapy pipeline.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.